Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Abscess

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children between 1 month and 17 years of age who undergo Incision and Drainage of a skin and soft tissue abscess by a member of the Children's Memorial Hospital pediatric surgery faculty.~Exclusion Criteria:~* Children who developed their infection while hospitalized or within 2 weeks of unrelated hospital discharge will be excluded.~* Children with surgical site infections will be excluded.~* Children with inherent or acquired immunodeficiency, including but not limited to transplant patients and patients on chemotherapy or systemic corticosteroids will be excluded.~* Patients admitted to the Infectious Disease service may be excluded at the discretion of the ID attending.~* Patients who are found to have no discreet fluid collections at the time of attempted incision and drainage will be excluded.~* Patients allergic or intolerant to both bactrim and clindamycin will be excluded.~* Patients with cellulitis greater than 5 cm beyond the lateral margin of the abscess (as determined by intraoperative measurements) will be excluded.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 5 days postoperative antibiotic (Type: EXPERIMENTAL): Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole \[bactrim\] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
- 1 day postoperative antibiotic (Type: EXPERIMENTAL): Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole \[bactrim\] (5mg/kg trimethoprim up to 160 mg, every 12 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).